Skip to main content

Table 1 Clinicopathological characteristics of the study population

From: Serum lnc34a is a potential prediction biomarker for bone metastasis in hepatocellular carcinoma patients

Variable

n of patients (%)

Age

  ≤ 56

78(49.7%)

  > 56

79(50.3%)

Gender

 male

142(90.4%)

 female

15(9.6%)

HBsAg

 negative

28(17.8%)

 positive

129(82.2%)

HCV-Ab

 negative

152(96.8%)

 positive

5(3.2%)

AFP

  ≤ 20

60(38.2%)

  > 20

97(61.8%)

ALT

  ≤ 40

126(80.3%)

  > 40

31(19.7%)

γ-GT

  ≤ 50

96(61.1%)

  > 50

61(38.9%)

Liver cirrhosis

 no

34(21.7%)

 yes

123(78.3%)

Child-Pugh score

 A

151(96.2%)

 B

6(3.8%)

Tumor differentiation

 I–II

93(59.2%)

 III–IV

64(40.8%)

Tumor size, cm

  ≤ 5

107(68.2%)

  > 5

50(31.8%)

Tumor number

 single

98(62.4%)

 multiple

59(37.6%)

Tumor encapsulation

 complete

72(45.9%)

 none

85(54.1%)

Vascular invasion

 no

112(71.3%)

 yes

45(28.7%)

BCLC stage

 0-A

99(63.1%)

 B-C

58(36.9%)

Lung metastasis

 no

134(85.4%)

 yes

23(14.6%)

Lymph node metastasis

 no

137(87.3%)

 yes

20(12.7%)

Bone metastasis

 no

139(88.5%)

 yes

18(11.5%)

Lnc34a

 low

77(49.0%)

 high

80(51.0%)

  1. HBsAg hepatitis B surface antigen, HCV-Ab hepatitis C virus antibody, AFP a-fetoprotein, ALT alanine aminotransferase, γ-GT γ-glutamyl transferase, BCLC-stage Barcelona Clinic Liver Cancer-stage